Subscribe

Marinomed Biotech AG (MARI.VI)

EUR8.95 +0.25 (+2.87%)
AT VIE Healthcare Biotechnology
Address Hovengasse 25 2100
Korneuburg, AT
CEO Andreas Grassauer
Website marinomed.com
IPO 2019-02-01
ISIN ATMARINOMED6

Explore sections of this company profile

Description

Marinomed Biotech AG is an Austrian-based biopharmaceutical firm dedicated to developing therapeutic solutions for viral and immunological conditions, with its market presence spanning across Austria, other European nations, and globally. Their comprehensive product pipeline includes Budesolv, which addresses allergic rhinitis and autoimmune gastritis, and Tacrosolv, currently undergoing Phase II clinical trials for anterior inflammatory eye diseases. Also featured in their development are Carravin, designed to alleviate nasal congestion, and Inhaleen, which is in Phase I clinical evaluation for viral pneumonia. Additionally, the company offers Carragelose, a range of products like nasal and throat sprays and lozenges, all formulated to combat viral respiratory infections. Established in 2006, the company was initially named Marinomed Biotechnologie GmbH, adopting its current name, Marinomed Biotech AG, in June 2017, and is headquartered in Korneuburg, Austria.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
EUR8.95 +0.25 (+2.87%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
3.8K
Beta
-0.19
Float Shares
1.32M
Free Float %
66.2%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
-0.50% +3.65% -22.87% -43.43% -49.75% -48.18% -39.70% -77.89% -92.04% -86.91% -86.91%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
8.95
Ratings Trend (MoM) 100% Bullish
Rating 2026-05 Change
Strong Buy 1 0
Buy 1 0
Hold 0 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
0.96
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
1 / 10
No MOAT
Composite Rating
D+
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
  • ✓
    Revenue growth Biotechnology: +1.6%
    +62.2% ★ Q1'25: +238.8% (vs Q3'23)
  • ✓
    EPS growth Biotechnology: +29.7%
    +196.0% ★ Q1'25: +1,001.4% (vs Q3'23)
  • ✓
    FCF margin FCF growth · Biotechnology: +16.2%
    +202.6% Q1'25: -14.5% (vs Q3'23)
  • ✓
    EBIT margin Biotechnology: +0.0%
    +242.9% ★ Q1'25: +340.3% (vs Q3'23)
  • ✓
    ROIC Biotechnology: -16.1%
    +1,978.0% ★
  • ✗
    Share dilution Biotechnology: -3.4%
    +3.5% Q1'25: +17.1% (vs Q3'23)
  • ✓
    Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×
    0.61× Q1'25: 0.12× (vs Q3'23)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (-0.16) × ERP
WACC = 61% × Ke + 39% × Kd (4.3%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Current price: 8.95
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2019
actual 		Dec 2020
actual 		Dec 2021
actual 		Dec 2022
actual 		Dec 2023
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
1 Rev. Ana.
1 EPS Ana. 		Dec 2027
1 Rev. Ana.
1 EPS Ana. 		Dec 2028
2 Rev. Ana.
1 EPS Ana. 		Dec 2029
1 Rev. Ana.
Revenue
6.14M
est: 5.01M (+22.5%)
8.12M
est: 7.85M (+3.5%)
11.63M
est: 22.10M (-47.4%)
11.28M
est: 11.20M (+0.7%)
9.18M
est: 6.42M (+43.1%)
4.75M
est: 3.50M (+35.6%)
7.70M
est: 7.70M (+0.0%)
8.95M
8.95M – 8.95M
+16.2% YoY
9.59M
9.59M – 9.59M
+7.1% YoY
9.83M
9.83M – 9.83M
+2.5% YoY
16.00M
16.00M – 16.00M
+62.8% YoY
EBITDA
-6.22M
est: -2.59M (-139.9%)
-4.86M
est: -4.06M (-19.8%)
-3.58M
est: -11.43M (+68.7%)
-3.21M
est: -5.79M (+44.5%)
-3.62M
est: -1.27M (-185.9%)
-7.18M
est: -690.9K (-939.3%)
19.00M
est: -1.52M (+1,350.0%)
-1.77M
-1.77M – -1.77M
-16.2% YoY
-1.89M
-1.89M – -1.89M
-7.1% YoY
-1.94M
-1.94M – -1.94M
-2.5% YoY
-3.16M
-3.16M – -3.16M
-62.8% YoY
EBIT
-6.55M
est: -2.83M (-131.2%)
-5.29M
est: -4.43M (-19.4%)
-4.19M
est: -12.48M (+66.5%)
-3.88M
est: -6.33M (+38.6%)
-4.30M
est: -1.51M (-185.7%)
-7.59M
est: -820.8K (-825.2%)
18.70M
est: -1.81M (+1,135.6%)
-2.10M
-2.10M – -2.10M
-16.2% YoY
-2.25M
-2.25M – -2.25M
-7.1% YoY
-2.30M
-2.30M – -2.30M
-2.5% YoY
-3.75M
-3.75M – -3.75M
-62.8% YoY
Net Income
-7.22M
est: -9.83M (+26.6%)
-6.01M
est: -6.45M (+6.8%)
-5.89M
est: 2.90M (-303.2%)
-6.40M
est: -8.25M (+22.5%)
-6.79M
-15.42M
est: -15.57M (+1.0%)
15.30M
est: 15.77M (-3.0%)
2.20M
2.20M – 2.20M
-86.0% YoY
2.75M
2.75M – 2.75M
+25.0% YoY
2.57M
2.57M – 2.57M
-6.7% YoY
—
— – —
-100.0% YoY
SGA
1.34M
est: 800.2K (+67.1%)
1.36M
est: 1.25M (+8.6%)
1.45M
est: 3.53M (-58.8%)
1.69M
est: 1.79M (-5.4%)
1.27M
est: 1.68M (-24.6%)
2.53M
est: 916.2K (+175.8%)
2.80M
est: 2.02M (+38.9%)
2.34M
2.34M – 2.34M
+16.2% YoY
2.51M
2.51M – 2.51M
+7.1% YoY
2.57M
2.57M – 2.57M
+2.5% YoY
4.19M
4.19M – 4.19M
+62.8% YoY
EPS
-5.09
est: -5.53 (+8.0%)
-4.09
est: -3.63 (-12.8%)
-3.99
est: 1.63 (-344.8%)
-4.27
est: -4.64 (+8.0%)
-4.48
-8.67
est: -8.46 (-2.5%)
8.32
est: 8.57 (-2.9%)
1.20
1.20 – 1.20
-86.0% YoY
1.49
1.49 – 1.49
+25.0% YoY
1.40
1.40 – 1.40
-6.7% YoY
—
— – —
-100.0% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-28 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-27 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-26 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-22 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-21 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-20 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-19 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-18 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-15 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-13 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-12 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-11 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-08 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-07 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-06 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-05 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-04 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-30 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-29 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-28 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-27 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-24 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-23 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-22 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-21 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-20 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-17 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
-6.92M
OE per share TTM
-4.53
Owner's Yield
-37.82%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
57.5%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock

This company is not held by any ETF in our universe.

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
6.0K
Shares Outstanding
2.00M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Gabriele Ram Chief Financial Officer & Member of Management Board 303.6K female
Andreas Grassauer Co-Founder, Chairman of Management Board & Chief Executive Officer 267.9K male
Eva Prieschl-Grassauer Co-Founder, Vice Chairwoman of Management Board & Chief Scientific Officer 255.9K female
Stephanie Kniep Head of Investor Relations — female
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Biotechnology